Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024
Amphastar Pharmaceuticals (NASDAQ:AMPH), a bio-pharmaceutical company specializing in technically challenging generic and proprietary injectable, inhalation, and intranasal products, has announced its second quarter 2024 earnings release and conference call. The company will disclose its financial results for the quarter ended June 30, 2024, after market close on Wednesday, August 7, 2024. A conference call to discuss these results is scheduled for 2:00 p.m. Pacific Time on the same day.
Investors can access the call by dialing 877-407-0989 (toll-free) or 201-389-0921 (international). The call will also be available via webcast on the company's website, with a replay accessible within 24 hours after the live call ends. Amphastar's products are primarily used in hospital or urgent care settings and are distributed through group purchasing organizations and drug wholesalers.
Amphastar Pharmaceuticals (NASDAQ:AMPH), un'azienda biofarmaceutica specializzata in prodotti generici e proprietari iniettabili, per inalazione e intranasali di difficile realizzazione tecnica, ha annunciato il suo rilascio dei risultati finanziari del secondo trimestre 2024 e la teleconferenza. L'azienda comunicherà i risultati finanziari per il trimestre concluso il 30 giugno 2024, dopo la chiusura del mercato, il mercoledì 7 agosto 2024. Una teleconferenza per discutere di questi risultati è prevista per le 14:00 ora del Pacifico dello stesso giorno.
Gli investitori possono accedere alla chiamata componendo 877-407-0989 (numero verde) o 201-389-0921 (internazionale). La chiamata sarà disponibile anche tramite webcast sul sito web dell'azienda, con una registrazione accessibile entro 24 ore dalla conclusione della chiamata dal vivo. I prodotti di Amphastar sono principalmente utilizzati in ospedali o strutture di pronto soccorso e sono distribuiti tramite organizzazioni di acquisto di gruppo e grossisti farmaceutici.
Amphastar Pharmaceuticals (NASDAQ:AMPH), una empresa biofarmacéutica especializada en productos inyectables, de inhalación e intranasales genéricos y de propiedad técnicamente desafiantes, ha anunciado su publicación de ganancias del segundo trimestre de 2024 y conferencia telefónica. La compañía dará a conocer sus resultados financieros para el trimestre que finalizó el 30 de junio de 2024, después del cierre del mercado, el miércoles 7 de agosto de 2024. Una conferencia telefónica para discutir estos resultados está programada para las 2:00 p.m. Hora del Pacífico del mismo día.
Los inversores pueden acceder a la llamada marcando 877-407-0989 (número gratuito) o 201-389-0921 (internacional). La llamada también estará disponible a través de una transmisión web en el sitio web de la empresa, con una repetición accesible dentro de las 24 horas posteriores al final de la llamada en vivo. Los productos de Amphastar se utilizan principalmente en hospitales o atención de urgencias y se distribuyen a través de organizaciones de compras grupales y mayoristas de medicamentos.
암파스타 제약(나스닥:AMPH)은 기술적으로 도전적인 제네릭 및 독점 주사제, 흡입제 및 비강 제품을 전문으로 하는 생물 제약 회사로, 2024년 2분기 실적 발표 및 컨퍼런스 콜을 발표했습니다. 회사는 2024년 6월 30일 기준 분기 재무 결과를 2024년 8월 7일 수요일 시장 종료 후 공개할 예정입니다. 같은 날 오후 2시 태평양 표준시에 이러한 결과를 논의하기 위한 컨퍼런스 콜이 예정되어 있습니다.
투자자는 877-407-0989 (무료) 또는 201-389-0921 (국제)로 전화하여 콜에 접속할 수 있습니다. 통화는 회사 웹사이트의 웹캐스트를 통해서도 이용 가능하며, 실시간 통화 종료 후 24시간 이내에 재생할 수 있습니다. 암파스타의 제품은 주로 병원 또는 응급 치료 환경에서 사용되며, 그룹 구매 조직 및 제약 도매업체를 통해 배포됩니다.
Amphastar Pharmaceuticals (NASDAQ:AMPH), une entreprise biopharmaceutique spécialisée dans des produits injectables, inhalables et intranasaux génériques et propriétaires d'une complexité technique, a annoncé son communiqué de résultats du deuxième trimestre 2024 et la conférence téléphonique. L'entreprise publiera ses résultats financiers pour le trimestre clos le 30 juin 2024, après la clôture du marché, le mercredi 7 août 2024. Une conférence téléphonique pour discuter de ces résultats est prévue pour 14h00 heure du Pacifique le même jour.
Les investisseurs peuvent accéder à l'appel en composant le 877-407-0989 (numéro gratuit) ou le 201-389-0921 (international). L'appel sera également disponible par webcast sur le site de l'entreprise, avec un replay accessible dans les 24 heures suivant la fin de l'appel en direct. Les produits d'Amphastar sont principalement utilisés dans les hôpitaux ou les services d'urgence et sont distribués par le biais d'organisations d'achat groupé et de grossistes en médicaments.
Amphastar Pharmaceuticals (NASDAQ:AMPH), ein biopharmazeutisches Unternehmen, das sich auf technisch anspruchsvolle generische und eigene injizierbare, inhalierbare und intranasale Produkte spezialisiert hat, hat seine Ergebnismitteilung für das zweite Quartal 2024 und die Telefonkonferenz angekündigt. Das Unternehmen wird seine finanziellen Ergebnisse für das am 30. Juni 2024 endende Quartal nach Börsenschluss am Mittwoch, den 7. August 2024 bekannt geben. Eine Telefonkonferenz zur Diskussion dieser Ergebnisse ist für 14:00 Uhr pazifischer Zeit am selben Tag geplant.
Investoren können an der Konferenz teilnehmen, indem sie 877-407-0989 (gebührenfrei) oder 201-389-0921 (international) anrufen. Der Anruf wird auch über einen Webcast auf der Website des Unternehmens verfügbar sein, mit einer Aufzeichnung, die innerhalb von 24 Stunden nach Beendigung des Live-Anrufs zugänglich ist. Die Produkte von Amphastar werden hauptsächlich in Krankenhäusern oder Notfallbehandlungen verwendet und über Gruppenbeschaffungsorganisationen und Arzneimittelgroßhändler vertrieben.
- None.
- None.
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 31, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Second quarter of 2024 ended June 30, 2024, after the market closes on Wednesday, August 7, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Forward Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the prospective benefits of the acquisition of BAQSIMI®, including its potential for continued revenue growth, the success of our integration of BAQSIMI®, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 10, 2024. In particular, there can be no guarantee that the acquisition of BAQSIMI® will be beneficial to our business, that any event, change or other circumstance could cause the results of the acquisition and integration of BAQSIMI® into our product portfolio to differ from Amphastar's expectation, that all or any of the contingent consideration will be payable on the terms described herein or at all, or that Amphastar can reliably predict the impact of BAQSIMI® on its financial results or financial guidance. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact:
Bill Peters
Chief Financial Officer
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
When will Amphastar Pharmaceuticals (AMPH) release its Q2 2024 earnings?
What time is Amphastar Pharmaceuticals' (AMPH) Q2 2024 earnings conference call?
How can investors access Amphastar Pharmaceuticals' (AMPH) Q2 2024 earnings call?
What products does Amphastar Pharmaceuticals (AMPH) specialize in?
